OR WAIT null SECS
Sartorius releases financial results for 2015, announcing a 16% increase in group sales revenue.
Germany-based biopharmaceutical company Sartorius Stedim Biotech released full-year financial results from 2015, citing a 16% increase in in-group sales revenue. The company posted total sales for the year at €1.1 billion (approximately $1.2 billion).
In a press announcement from the company, Joachim Kreuzburg, CEO of Sartorius, attested the company’s jump in revenue was due an increase in sales in Sartorius’ Bioprocess Solutions Division, which focuses on single-use products for the manufacture of biopharmaceuticals. The division itself experienced a 20.9% increase in sales revenue during 2015.
"In 2015, our growth driver was the Bioprocess Solutions Division yet again. As a supplier for the biopharmaceutical industry, we operate in an exceptionally dynamic market where we also gained further share," said Kreuzberg. "Our Lab Products & Services Division performed well in the past year, too. For 2016, our outlook is positive and over the medium-term, we also continue to see ourselves on track to grow significantly and profitably."
High demand for single-use solutions added to the increase in the company’s profitability. Sartorius also noted the acquisition of BioOutsource Ltd. And Cellca GmbH had an impact on sales, “contributing nearly two percentage points in constant currencies to the divisions sales expansion.” As a result of this jump in sales, the company has set sales targets (before interest, taxes, depreciation, and amortization) to reach around €2 billion for the full year of 2020.